World Journal of Surgery

, Volume 32, Issue 7, pp 1278–1284 | Cite as

Evidence-based Management of Toxic Multinodular Goiter (Plummer’s Disease)

  • John R. PorterfieldJr.
  • Geoffrey B. Thompson
  • David R. Farley
  • Clive S. Grant
  • Melanie L. Richards
Article

Abstract

Background

Toxic multinodular goiter (Plummer’s disease) has posed challenges to surgeons, endocrinologists, and radiation oncologists since its description in 1913. A literature review with evidenced-based methodology has not yet been reported.

Methods

A systematic review of the English literature from 1950 to 2007 and report of Mayo Clinic experience since 1950 was undertaken to establish evidence-based recommendations for management.

Results

Surgery and radioactive iodine (RI) are both supported by level IV evidence in the treatment of solitary toxic nodules and toxic multinodular goiter, and treatment is determined by symptoms and co-morbidities. No evidence suggests a difference in treatment outcome based on pretreatment clinical or subclinical hyperthyroidism. Level IV evidence supports thyroidectomy over RI for large goiters. When compressive symptoms are present, level IV evidence supports thyroidectomy for maximal symptom relief in patients at moderate risk. Occult malignancies are found in 2–3% of thyroidectomy specimens for Plummer’s disease. Despite technical reports of RI dose considerations, there are no prospective studies validating a dose formula. Ethanol ablation of toxic nodules in patients unfit for surgery is supported by level III evidence. Level V data suggest a cost benefit favoring surgery.

Conclusions

Treatment of Plummer’s disease with antithyroid medications, ethanol ablation, RI ablation, or surgery must balance the goals of therapy, durability of cure, relief of symptoms, risk of malignancy, and risk of complications. Between 1950 and 2006, 948 (70%) of 1,356 patients with Plummer’s disease have been treated surgically at Mayo Clinic.

Notes

Acknowledgments

Special thanks to Linda L. Haigh and Michelle A. Neseth for their assistance in preparing the final manuscript.

References

  1. 1.
    Plummer H (1913) The clinical and pathologic relationship of hyperplastic and nonhyperplastic goiters. JAMA 61:650Google Scholar
  2. 2.
    Vitti P, Rago T, Tonacchera M et al (2002) Toxic multinodular goiter in the elderly. J Endocrinol Invest 25:16–18PubMedGoogle Scholar
  3. 3.
    Sackett DL (1989) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95:2–4CrossRefGoogle Scholar
  4. 4.
    Wahl RA, Rimpl I, Saalabian S et al (1998) Differentiated operative therapy of thyroid autonomy (Plummer’s disease). Exp Clin Endocrinol Diabetes 106(Suppl 4):S78–S84PubMedCrossRefGoogle Scholar
  5. 5.
    Sawin CT, Geller A, Wolf PA et al (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249–1252PubMedCrossRefGoogle Scholar
  6. 6.
    Iervasi G, Molinaro S, Landi P et al (2007) Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167:1526–1532PubMedCrossRefGoogle Scholar
  7. 7.
    Erdogan MF, Kucuk NO, Anil C et al (2004) Effect of radioiodine therapy on thyroid nodule size and function in patients with toxic adenomas. Nucl Med Commun 25:1083–1087PubMedCrossRefGoogle Scholar
  8. 8.
    Hamburger J, Hamburger S (1985) Diagnosis and management of large toxic multinodular goiters. J Nucl Med 26:888–892PubMedGoogle Scholar
  9. 9.
    Alexopoulou O, Beguin C, Buysschaert M et al (2004) Predictive factors of thyroid carcinoma in non-toxic multinodular goitre. Acta Clin Belg 59:84–89PubMedGoogle Scholar
  10. 10.
    Clerc J, Dagousset F, Izembart M et al (1995) Radioiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity. J Nucl Med 36:217–223 PubMedGoogle Scholar
  11. 11.
    Lippi F, Ferrari C, Manetti L et al (1996) Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: results of an Italian multicenter study. The Multicenter Study Group. J Clin Endocrinol Metab 81:3261–3264CrossRefGoogle Scholar
  12. 12.
    Zingrillo M, Modoni S, Conte M et al (2003) Percutaneous ethanol injection plus radioiodine versus radioiodine alone in the treatment of large toxic thyroid nodules. J Nucl Med 44:207–210PubMedGoogle Scholar
  13. 13.
    Vidal-Trecan GM, Stahl JE, Eckman MH (2004) Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid 14:933Google Scholar
  14. 14.
    Jensen MD, Gharib H, Naessens JM et al (1986) Treatment of toxic multinodular goiter (Plummer’s disease): surgery or radioiodine? World J Surg 10:673–680PubMedCrossRefGoogle Scholar
  15. 15.
    Erickson D, Gharib H, Li H et al (1998) Treatment of patients with toxic multinodular goiter. Thyroid 8:277–281PubMedCrossRefGoogle Scholar
  16. 16.
    Kang AS, Grant CS, Thompson GB et al (2002) Current treatment of nodular goiter with hyperthyroidism (Plummer’s disease): surgery versus radioiodine. Surgery 132:916–923PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2008

Authors and Affiliations

  • John R. PorterfieldJr.
    • 1
  • Geoffrey B. Thompson
    • 1
  • David R. Farley
    • 1
  • Clive S. Grant
    • 1
  • Melanie L. Richards
    • 1
  1. 1.Department of SurgeryMayo ClinicRochesterUSA

Personalised recommendations